{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:39:55Z","timestamp":1794973195763,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7954","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function\n                    <jats:sup>1\u20133<\/jats:sup>\n                    . The interaction of menin with lysine methyltransferase\u20092A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of\n                    <jats:italic>KMT2A<\/jats:italic>\n                    or mutation of the nucleophosmin\u20091 gene\u00a0(\n                    <jats:italic>NPM1<\/jats:italic>\n                    )\n                    <jats:sup>4\u20136<\/jats:sup>\n                    .\n                    <jats:italic>KMT2A<\/jats:italic>\n                    rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas\n                    <jats:italic>NPM1<\/jats:italic>\n                    mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia\n                    <jats:sup>7,8<\/jats:sup>\n                    . Here, we describe the results of the first-in-human phase\u20091 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin\u2013KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399). We show that therapy with revumenib was associated with a low frequency of grade\u20093 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR\/CRh) in the efficacy analysis population. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. Remissions occurred in leukaemias refractory to multiple previous lines of therapy. We demonstrate clearance of residual disease using sensitive clinical assays and identify hallmarks of differentiation into normal haematopoietic cells, including differentiation syndrome. These data establish menin inhibition as a therapeutic strategy for susceptible acute leukaemia subtypes.\n                  <\/jats:p>","DOI":"10.1038\/s41586-023-05812-3","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T13:04:34Z","timestamp":1678885474000},"page":"920-924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":540,"title":["The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia"],"prefix":"10.1038","volume":"615","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-3133","authenticated-orcid":false,"given":"John","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Dickens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-4728","authenticated-orcid":false,"given":"Scott A.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Perner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca G.","family":"Bagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ordentlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"McGeehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"5812_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111\u2013121 (2013).","journal-title":"N. Engl. J. Med."},{"key":"5812_CR2","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386\u20132398 (2018).","journal-title":"N. Engl. J. Med."},{"key":"5812_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722\u2013731 (2017).","journal-title":"Blood"},{"key":"5812_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207\u2013218 (2005).","journal-title":"Cell"},{"key":"5812_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka, J. et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8, 277\u2013284 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"5812_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MW K\u00fchn","year":"2016","unstructured":"K\u00fchn, M. W. et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 6, 1166\u20131181 (2016).","journal-title":"Cancer Discov."},{"key":"5812_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823\u2013833 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"5812_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"5812_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa, G. C. et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia 35, 2482\u20132495 (2021).","journal-title":"Leukemia"},{"key":"5812_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1128\/MCB.21.1.224-234.2001","volume":"21","author":"U Thorsteinsdottir","year":"2001","unstructured":"Thorsteinsdottir, U., Kroon, E., Jerome, L., Blasi, F. & Sauvageau, G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol. Cell. Biol. 21, 224\u2013234 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"5812_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/378505a0","volume":"378","author":"BD Yu","year":"1995","unstructured":"Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A. J. & Korsmeyer, S. J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378, 505\u2013508 (1995).","journal-title":"Nature"},{"key":"5812_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","volume":"367","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann, H. J. et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586\u2013590 (2020).","journal-title":"Science"},{"key":"5812_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov, A. V. et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell 36, 660\u2013673 (2019).","journal-title":"Cancer Cell"},{"key":"5812_CR14","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","volume":"123","author":"MA Sanz","year":"2014","unstructured":"Sanz, M. A. & Montesinos, P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123, 2777\u20132782 (2014).","journal-title":"Blood"},{"key":"5812_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","volume":"4","author":"AT Fathi","year":"2018","unstructured":"Fathi, A. T. et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study. JAMA Oncol. 4, 1106\u20131110 (2018).","journal-title":"JAMA Oncol."},{"key":"5812_CR16","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","volume":"26","author":"KJ Norsworthy","year":"2020","unstructured":"Norsworthy, K. J. et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin. Cancer Res. 26, 4280\u20134288 (2020).","journal-title":"Clin. Cancer Res."},{"key":"5812_CR17","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama, M. M. et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood 136, 2442\u20132456 (2020).","journal-title":"Blood"},{"key":"5812_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa, G. C. et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 11, 162 (2021).","journal-title":"Blood Cancer J."},{"key":"5812_CR19","doi-asserted-by":"publisher","first-page":"26340","DOI":"10.1073\/pnas.2014732117","volume":"117","author":"M Bill","year":"2020","unstructured":"Bill, M. et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A. Proc. Natl Acad. Sci. USA 117, 26340\u201326346 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5812_CR20","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade, D. et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J. Clin. Oncol. 27, 3650\u20133658 (2009).","journal-title":"J. Clin. Oncol."},{"key":"5812_CR21","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood.V80.10.2604.2604","volume":"80","author":"M Andreeff","year":"1992","unstructured":"Andreeff, M. et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80, 2604\u20132609 (1992).","journal-title":"Blood"},{"key":"5812_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","volume":"108","author":"JM Hilden","year":"2006","unstructured":"Hilden, J. M. et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children\u2019s Oncology Group. Blood 108, 441\u2013451 (2006).","journal-title":"Blood"},{"key":"5812_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters, R. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370, 240\u2013250 (2007).","journal-title":"Lancet"},{"key":"5812_CR24","doi-asserted-by":"publisher","unstructured":"Perner, F. et. al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature https:\/\/doi.org\/10.1038\/s41586-023-05755-9 (2023).","DOI":"10.1038\/s41586-023-05755-9"},{"key":"5812_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.2021012806","volume":"139","author":"EB Heikamp","year":"2021","unstructured":"Heikamp, E. B. et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood 139, 894\u2013906 (2021).","journal-title":"Blood"},{"key":"5812_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41375-021-01146-z","volume":"35","author":"C Libbrecht","year":"2021","unstructured":"Libbrecht, C. et al. Menin is necessary for long term maintenance of meningioma-1 driven leukemia. Leukemia 35, 1405\u20131417 (2021).","journal-title":"Leukemia"},{"key":"5812_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","volume":"26","author":"JM Skolnik","year":"2008","unstructured":"Skolnik, J. M. et al. Shortening the timeline of pediatric phase I trials: the rolling six design. J. Clin. Oncol. 26, 190\u2013195 (2008).","journal-title":"J. Clin. Oncol."},{"key":"5812_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"5812_CR29","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","volume":"20","author":"F Buccisano","year":"2006","unstructured":"Buccisano, F. et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20, 1783\u20131789 (2006).","journal-title":"Leukemia"},{"key":"5812_CR30","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn, M. et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J. Clin. Oncol. 31, 3889\u20133897 (2013).","journal-title":"J. Clin. Oncol."},{"key":"5812_CR31","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman, S. D. et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J. Clin. Oncol. 31, 4123\u20134131 (2013).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05812-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T11:05:19Z","timestamp":1680087919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":31,"journal-issue":{"issue":"7954","published-print":{"date-parts":[[2023,3,30]]}},"alternative-id":["5812"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-05812-3","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.C.I. received consultancy or advisory role fees from Novartis, Kura Oncology and NuProbe and received research funding from Celgene, Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology and NuProbe. I.A. received consultancy or advisory role fees from Amgen, Pfizer, Jazz, AbbVie and Agios, research funding from AbbVie and Macrogenics and honoraria from Amgen, Pfizer, Jazz, AbbVie and Agios. J.D.P. has a consultancy role with Incyte and RiverVest Venture Partners, has served as a board member or advisory committee member for RiverVest Venture Partners, Magenta, hC Bioscience, Inc. and WUGEN, has received research funding from NeoImmune Tech, Macrogenics, Incyte, Bioline Rx and WUGEN and holds patents or pending patents for UCART7 for treatment of T-ALL, VLA-4 inhibitors for stem cell mobilization and NT-I7 for CART expansion. R.S. has served on the steering committee of AbbVie and advisory boards of AbbVie, AvenCell, CTI Pharma, Kura One, Genentech, Actinium, Arog, BMS, Boston Pharmaceuticals, GSK, Janssen, Jazz, Novartis, Syros, Takeda, Elevate Bio, Syndax Pharmaceuticals, Gemoab, BerGenBio, Foghorn Tera, Aprea, Innate, Actinium and OncoNova; served as DSMB for Aptevo, Epizyme, Takeda and Syntrix\/ACI Clinical; on the focus group of BerGenBio; and on AML Expert Council of GSK and Grand Rounds of Jazz Pharmaceuticals. M.A. has served on the advisory boards of Kite Pharma and Syndax Pharmaceuticals. M.J.T. has a consulting or advisory role with AbbVie and CVS, has an expert testimony role with Apotex and received research funding from AbbVie, Gilead Sciences, Janssen, Merck, Pharmacyclics, Syndax\u00a0Pharmaceuticals, TG Therapeutics and Tolero. M.R.P. served in a leadership role with ION Pharma; received honoraria from Pfizer, Pharmacyclics, Bayer, Janssen Oncology, Genentech and Adaptive Biotechnologies; has a consulting or advisory role with Pharmacyclics\/Janssen and Pfizer\/EMD Serono; served on the Speakers\u2019 Bureau of Exelixis, Genentech\/Roche, Taiho Pharmaceutical and Celgene; and received research funding from Acerta Pharma, ADC Therapeutics, Agenus, Aileron Therapeutics, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Celgene, Checkpoint Therapeutics, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, EMD Serono, Evelo Therapeutics, FORMA Therapeutics, Genentech\/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, Pfizer, Placon, Portola Pharmaceuticals, Prelude Therapeutics, Ribon Therapeutics, Seven and Eight Biopharmaceuticals, Syndax\u00a0Pharmaceuticals, Taiho Pharmaceutical, Takeda, Tesaro, TopAlliance BioSciences, Inc., Vigeo, ORIC, Artios, IgM Biosciences, Puretech, BioTheryX, Black Diamond Therapeutics, IgM Biosciences, NGM Biopharmaceuticals, Nurix, PureTech, Relay Therapeutics, Samumed, Silicon Therapeutics, TeneoBio, Treadwell Therapeutics, Zymeworks, Olema, Adagene, Astellas, NGM, Accutar Biotech, TeneoBio, Novartis, Compugen, Black Diamond Therapeutics, MabSpace Biosciences, Immunogen and Blueprint Pharmaceuticals. D.S.D. has a consulting or advisory role with Tempus, Inc. S. Shenoy has a consulting or advisory role with Artio, BMS and Takaeda. H.K. received honoraria\/advisory board\/consulting fees from AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, Stemline and Takeda; and received research funding from AbbVie, Amgen, Ascentage, BMS, Daiichi Sankyo, Immunogen, Jazz, and Novartis. S.A.A. received stock or other ownership from Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics and Mana Therapeutics; has a consulting or advisory role with Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics, Mana Therapeutics and Twentyeight-Seven Therapeutics; received research funding from Syndax Pharmaceuticals\u00a0and Janssen; and holds patents, royalties and other intellectual property for MENIN inhibition in NPM1 AML: WO\/2017\/132398A1. G.R. is a former employee of Syndax Pharmaceuticals and a current employee of Boston Pharmaceuticals. R.G.B. is an employee of Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals. M.L.M., P.O. and G.M.M. are employees of Syndax Pharmaceuticals. M.L.M. has a consulting or advisory role at Nuvalent, holds patents, royalties and other intellectual property at Syndax Pharmaceuticals and Nuvalent and has stock or other ownership at Syndax Pharmaceuticals and Johnson & Johnson. P.O. has a consulting or advisory role at Patrys and Twentyeight-Seven Therapeutics, holds patents, royalties and other intellectual property at Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals. G.M.M. has a consulting or advisory role at Syndax Pharmaceuticals, holds patents, royalties and other intellectual property at Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals. Y.G. is an employee of Syndax Pharmaceuticals and has stock or other ownership at Syndax Pharmaceuticals and AstraZeneca. S. Smith has a consultancy or advisory role with Syndax Pharmaceuticals. E.M.S. has a consulting or advisory role with Gilead, CTI Biopharma, Epizyme, AbbVie, Pinotbio, Neoleukin Genesis, Genentech, Jazz, Novartis, Celgene, Calithera, Takeda, Janssen, BMS, Kronos, Kura, Auron, Syndax Pharmaceuticals, Servier, Agios and Remix and received research funding from Biotheryx, Agios, Servier, Eisai, BMS, Bayer, Syndax, Syros and Loxo. B.C., F.P., J.A.P., N.S. and V.K. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}